Neurocrine Biosciences Inc

NBIX

NASDAQ. Currency in USD

126.31 -0.75 ( -0.59% )

Real time prices: December 01

Market Cap.
12.14B
Beta (5Y monthly)
0.52
Price/Earnings
208.72
EPS (TTM)
0.57
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
654,342
1y Target Est.
127.58
Day's Range
125.64
-
129.29
52 Week's Range
71.88
-
129.29

Historical Summary

Performance
EPS growth
Share Buybacks

About Neurocrine Biosciences Inc

Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Website
https://www.neurocrine.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
94.87M
Employees
1150
Address
12780 El Camino Real, San Diego, CA, United States, 92130
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Latest news

Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10....
By Benzinga - 2 weeks ago

Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance

Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due...
By Zacks Investment Research - 4 weeks ago

Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter...
By Zacks Investment Research - 4 weeks ago

Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a...
By Zacks Investment Research - 5 weeks ago

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings...
By Zacks Investment Research - 5 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

Upgrades According to Deutsche Bank, the prior rating for Scorpio Tankers Inc (NYSE:STNG) was changed...
By Benzinga - 7 weeks ago

3 Top Biotech Stocks Defying the Bear Market
3 Top Biotech Stocks Defying the Bear Market

Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
By The Motley Fool - 7 weeks ago

4 Analysts Have This to Say About Neurocrine Biosciences
4 Analysts Have This to Say About Neurocrine Biosciences

Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings: Bullish Somewhat...
By Benzinga - 9 weeks ago